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A B S T R A C T   
Pregnancy demands major cardiovascular, renal and endocrine changes to provide an adequate blood supply for 
the growing fetus. The renin-angiotensin-aldosterone system plays a key role in this adaptation process. One of 
its components, prorenin, is released in significant amounts from the ovary and uteroplacental unit. This review 
describes the sources of prorenin in the periconception period and in pregnancy, including its modulation by in- 
vitro fertilization protocols, and discusses its potential effects, among others focusing on preeclampsia. It ends 
with discussing the long-term consequences, even in later life, of inappropriate renin-angiotensin-aldosterone 
system activity in pregnancy and offers directions for future research. Ultimately, a full understanding of the 
role of prorenin periconceptionally and during pregnancy will help to develop tools to diagnose and/or prevent 
reproductive complications.   
1. Introduction 
Successful conception and the subsequent physiologic adaptation to 
pregnancy involves the complex coordination of different organ sys-
tems, including the endocrine, cardiovascular and renal systems, to 
ensure the well-being of the mother and the fetus during pregnancy. 
These changes start in the luteal phase of the menstrual cycle and peak at 
the end of the first trimester prior to the increase in metabolic demands 
of mother and fetus and in anticipation of growing needs in the second 
half of pregnancy (Fig. 1). Systemic vasodilation occurs as early as 3 
weeks post-conception (5 weeks gestation) (Chapman et al., 1998), and 
is accompanied by a decrease in peripheral vascular resistance, reaching 
a nadir during the mid-second trimester. A first reduction in maternal 
systolic, diastolic and mean arterial blood pressure is observed at a 
median of 6 weeks gestation, with a return to non-pregnant levels during 
the last month of pregnancy (Mahendru et al., 2012; Chapman et al., 
1998; Robson et al., 1989; Capeless and Clapp, 1989; Robb et al., 2009). 
Heart rate increases in early pregnancy, while cardiac output and left 
atrial dimension increase from preconception to mid-gestation, with a 
decline after 32–35 weeks of gestation. Carotid femoral pulse wave 
velocity and augmentation index decline continuously from baseline 
preconception levels. Reductions in renal afferent and efferent arteriolar 
resistance result in rises in renal plasma flow, ([RPF], by 50–80%) and 
glomerular filtration rate ([GFR], by 40–65%) (Sims and Krantz, 1958; 
De Alvarez, 1958; Assali et al., 1959; Roberts et al., 1996; Dunlop, 
1981). This will increase creatinine and urea clearances, thereby 
lowering their plasma level (Roberts et al., 1996; Sims and Krantz, 1958; 
Kuhlback and Widholm, 1966; Nice, 1935). 
The renin-angiotensin-aldosterone system (RAAS) is a key player in 
this adaptation process. Renin cleaves angiotensin (Ang) I from angio-
tensinogen, which is subsequently converted by ACE into Ang II, a 
potent vasoconstrictor and growth factor which also stimulates the 
synthesis of aldosterone. Increases in Ang II and aldosterone levels are 
necessary to achieve the 30–40% increase in intravascular volume that 
is required in normal pregnancy to allow the above-described changes. 
Rises in Ang II particularly depend on increases in renin and angio-
tensinogen, and to a lesser degree on increases in angiotensin-converting 
enzyme (ACE) (Danser et al., 1998, 2007). Remarkably, the levels of 
renin’s precursor, prorenin, also increase substantially in pregnant 
women. This is unexpected, since prorenin is inactive (due to the fact 
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that a so-called prosegment covers its active site; Fig. 2), raising the 
question why prorenin would rise at all. Normally under conditions 
where the RAAS is activated, e.g. in heart failure and patients with renal 
artery stenosis, it is renin rather than prorenin which rises (Danser et al., 
1997; Klotz et al., 2009). Indeed, particularly during additional 
blockade of the RAAS with RAAS inhibitors, renin rises may be >
100-fold (Balcarek et al., 2014; Klotz et al., 2009). To display activity, 
prorenin needs to be converted to renin. This proteolytic process in-
volves the cleavage of the prosegment by an as yet unknown enzyme, 
and is limited to the kidney. Of interest, under physiological conditions 
(pH 7.4, 37 ◦C), a small fraction of prorenin (≈1% or less) occurs in a 
so-called ‘open’ conformation, i.e., a conformation where the proseg-
ment has moved out of the enzymatic cleft (Schalekamp et al., 2008) 
(Fig. 2). Hence, it no longer covers the cleft, and thus such prorenin is 
able to display enzymatic activity to the same degree as renin, although 
its prosegment is still present (Schalekamp et al., 2008). Theoretically, 
particularly under conditions where prorenin levels are high (like in 
pregnancy) this ‘non-proteolytic’ activation of prorenin could contribute 
to Ang I generation in blood. Studies in transgenic animals with exces-
sively high prorenin levels (Campbell et al., 2009) support this view, but 
in-vivo data in humans confirming this phenomenon are lacking. A 
further possibility, actively studied over the last 20 years, is that pro-
renin binds to a receptor, which then facilitates non-proteolytic activa-
tion. According to this theory, prorenin might contribute to angiotensin 
generation at any non-renal tissue site simply by binding to its receptor, 
without the need for a prosegment-cleaving enzyme. This is a very 
attractive theory, particularly because humans have relatively high 
prorenin levels which increase even further due to unknown reasons in 
conditions like pregnancy and diabetes. The presence of a receptor 
would finally explain why prorenin exists at all. A putative candidate 
was proposed nearly 20 years ago, the so-called (pro)renin receptor 
(Nguyen et al., 2002). It not only allowed prorenin to display Ang 
I-generating activity, but also to act as an angiotensin-independent 
agonist. However, prorenin-(pro)renin receptor interaction required 
prorenin levels in the nanomolar range (Batenburg et al., 2011), i.e. 
many orders of magnitude above its normal levels, even under condi-
tions where its levels have increased (like in pregnancy). Thus, such 
interaction is highly unlikely to ever occur in vivo (except in transgenic 
animals), and more recent studies suggest that the (pro)renin receptor 
rather exerts RAAS-independent functions (Lu et al., 2016; Ren et al., 
2018). 
This paper describes the source(s) of prorenin during the peri-
conception period and in pregnancy, and discusses its regulators and 
potential role(s), among others focusing on preeclampsia, where elegant 
transgenic models have yielded novel insights. It ends with discussing 
the long-term consequences of inappropriate RAAS activity in 
Fig. 1. Adaptation of endocrine, cardiovascular and renal parameters from preconceptional baseline throughout pregnancy and postpartum. AI, augmentation index; 
AU, arbitrary units; CO, cardiac output; GFR, glomerular filtration rate; hCG, human chorionic gonadotropin; MAP, mean arterial pressure; RPF, renal plasma flow; 
SVR, systemic vascular resistance. 
Fig. 2. Renin and prorenin conformations. Under physiological conditions (pH 
7.4, 37 ◦C), a small fraction of prorenin (≈1% or less) occurs in the so-called 
‘open’ conformation, i.e., a conformation where the prosegment has moved 
out of the enzymatic cleft, thus allowing it to react with angiotensinogen to 
yield angiotensin I. Yet, the majority of prorenin is closed and inactive. 
Cleavage of the prosegment (also known as ‘proteolytic’ activation) occurs 
exclusively in the kidney, and depends on an as yet unidentified enzyme. 
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pregnancy, and offers directions for future research. 
2. Circulating renin-angiotensin-aldosterone system in 
pregnancy: source(s) of prorenin 
Circulating angiotensinogen levels increase 3-5-fold in pregnant 
women (Verdonk et al., 2015). This is due to estrogen-stimulated 
upregulation of hepatic angiotensinogen synthesis (Klett et al., 1992; 
Uijl et al., 2019). The rise in angiotensinogen is accompanied by a 
modest (≈1.5-2-fold) rise in the concentration of plasma renin, either 
due to the decrease in blood pressure (affecting renal afferent/efferent 
arteriolar tone and renal JG cell responsiveness) or the fact that pro-
gesterone acts as an antagonist towards the mineralocorticoid receptor 
(Landau and Lugibihl, 1958). Together, the upregulation in plasma 
renin concentration and angiotensinogen result in a 2-3-fold rise in 
plasma renin activity (PRA), thereby raising Ang I and II levels 
throughout pregnancy. Remarkably, the Ang II elevation does not result 
in a rise in blood pressure. In fact, the constrictor sensitivity to exoge-
nous Ang II is diminished in pregnancy. This could relate to a down-
regulation of constrictor Ang II type 1 (AT1) receptors, an upregulation 
of dilator Ang II type 2 (AT2) receptors, and/or the upregulation of 
counterbalancing dilator mechanisms including nitric oxide (NO), 
prostaglandins and the Ang-(1–7)/Mas receptor axis (Mishra et al., 
2019; Gant et al., 1980; Verdonk et al., 2014; South et al., 2019). Renin 
levels fall within 24 h after delivery, thus allowing a rapid 
post-pregnancy normalization of circulating Ang II and aldosterone 
(Derkx et al., 1987). Angiotensinogen levels fall less rapidly, possibly 
due to puerperal activity of the corpus luteum, resulting in continued 
estrogen release after birth (Wier et al., 1975; Weiss and Rifkin, 1975; 
Conrad et al., 2019a). 
Prorenin levels increase 4-5-fold by week 8, and drop only slowly 
after delivery over a period of several days (Sealey et al., 1985; Derkx 
et al., 1987). The latter contrasts with the rapid decrease of renin after 
pregnancy, and is suggestive for an extrarenal source of prorenin with 
continued activity after birth. The much higher rise in prorenin rapidly 
after conception and during pregnancy (versus renin) also supports an 
extrarenal source. Studies in pregnancies lacking a corpus luteum 
(Fig. 3) have revealed that the corpus luteum is the major contributor to 
this rise in circulating prorenin, as well as its continued synthesis after 
birth. Indeed, no such increase in circulating prorenin was seen in 
pregnancies without a corpus luteum (Derkx et al., 1987). In such 
pregnancies, the prorenin rise was as modest as the rise in renin, and 
prorenin decreased in parallel with renin after parturition (Sealey et al., 
1985; Derkx et al., 1987). Recent data obtained in 277 women with 
either no corpus luteum, 1 corpus luteum or >1 corpus luteum further 
confirmed the direct relationship between corpus luteum number and 
prorenin levels (Wiegel et al., 2020). Taken together, these data indicate 
that renin upregulation in pregnancy is kidney-driven, while the ovaries 
are the main source of prorenin levels in pregnant women. 
Chorionic and amniotic fluid contain prorenin levels that are many 
orders of magnitude above those in blood. Early in pregnancy the cho-
rionic cavity is larger, while it disappears after 8 weeks, when human 
chorionic gonadotropin (hCG) levels decline and the amniotic cavity 
becomes predominant (Itskovitz et al., 1992). The amniotic tissue does 
not synthesize prorenin, and it is believed that chorionic prorenin passes 
through the amnion into the amniotic fluid. Since the amniotic fluid 
levels of prorenin were normal in pregnancies without a corpus luteum 
(Derkx et al., 1987), it appears that chorionic prorenin does not 
contribute to the levels of prorenin in plasma. Other potential sources of 
circulating prorenin are the uterus and placenta. Indeed, making use of 
the isolated perfused cotyledon setup, Lenz et al. were able to demon-
strate prorenin release to the maternal but not the fetal circulation (Lenz 
et al., 1991). Direct evidence for decidual prorenin release into the 
circulation is not available. Yet, it may contribute to gestational fluid 
prorenin (Shaw et al., 1989). Moreover, Brar et al. demonstrated pro-
renin release from the uteroplacental unit in pregnant women (Brar 
et al., 1986). This conclusion was based on the presence of higher pro-
renin levels in uterine venous blood versus arterial blood. No such dif-
ferences were observed for renin. In summary, next to the ovary and 
kidneys, a third (and probably modest) source of circulating prorenin in 
pregnancy is the uteroplacental unit. Lenz et al. estimated that <5% of 
circulating prorenin in pregnancy originates from the placenta (Lenz 
et al., 1991). The very modest rises in prorenin in a woman without a 
corpus luteum, also at late term (Derkx et al., 1987), is in agreement 
with this view. 
Prorenin levels in blood normally are around 10 times higher than 
those of renin (Danser et al., 1998). In pregnancy, with renin increasing 
<2-fold, and prorenin increasing 4-5-fold, this results in renin levels 
representing <5% of total renin (=renin + prorenin). Under such con-
ditions, a small fraction of prorenin displaying activity (Fig. 2) might 
Fig. 3. Physiological follicle development followed by spontaneous conception with one corpus luteum compared to pregnancies achieved through assisted 
reproduction with fresh embryo transfer (ET) after superovulation with multiple corpora lutea or frozen ET in a natural cycle with one corpus luteum or frozen ET in 
a programmed cycle after suppression of the pituitary-ovarian axis in the absence of a corpus luteum. 
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contribute to Ang I generation in blood to the same degree as renin. 
Initial studies linked prorenin to vasodilation, albeit via an unknown 
mechanism (Sealey et al., 1991, 1996). Direct prorenin-induced effects 
(e.g., independent of Ang II formation) may involve a receptor, and 
although the (pro)renin receptor has been suggested to be this receptor 
(Pringle et al., 2015), convincing evidence that it plays such a role in 
vivo is lacking (Batenburg et al., 2011). 
3. Corpus luteum, early gestational hemodynamic adaptation 
and circulating prorenin 
In conceptions lacking a corpus luteum the systemic and renal ad-
aptations in the first weeks of pregnancy are attenuated. This is sug-
gestive for a critical role of corpus luteum factors in the maternal 
hemodynamic adaptation in early gestation (von Versen-Höynck et al., 
2019; Conrad et al., 2019b). Indeed, the corpus luteum is considered a 
‘functional ovarian cyst’ during early pregnancy, i.e., before the 
luteal-placental shift, when placental hormones (synthesized by syncy-
tiotrophoblast cells) become of greater importance. Moreover, pro-
spective cohort studies in infertile populations showed that the risk to 
develop preeclampsia is doubled in women who lack a corpus luteum 
(von Versen-Höynck et al., 2019; Ginstrom Ernstad et al., 2019). The 
corpus luteum evolves from remnant tissue of the ovulated follicle with 
the preovulatory surge of luteinizing hormone (LH) from the pituitary 
gland as the main stimulus. It has significant steroidogenic and angio-
genic activity in both the luteal phase of a menstrual cycle and in early 
pregnancy (Devoto et al., 2009). Transformation of the follicle into the 
corpus luteum involves vascular endothelial cells undergoing intense 
proliferation and the formation of a rich vascular network, essential for 
the delivery of substrates. 
A physiological pregnancy is preceded by one corpus luteum. In 
contrast, pregnancies achieved via ovulation stimulation treatment 
often begin in a non-physiological endocrine milieu due to suppression 
of the pituitary-ovarian axis and the absence of the corpus luteum or due 
to superovulation with the presence of more than one corpus luteum 
(Fig. 3). Corpus luteum function is controlled by the interaction of 
several hormones secreted by the pituitary gland, and in case of preg-
nancy, by the decidua and the placenta. It contains steroidogenic cells 
(theca-lutein [small luteal cells] and granulosa-lutein cells [large luteal 
cells]) and non-steroidogenic cells (endothelial cells, pericytes, fibro-
blasts and immune cells) (Davis and Rueda, 2002; Alila and Hansel, 
1984). The corpus luteum synthesizes hormones, growth factors, 
angiogenic factors and vasoactive substances to establish and maintain 
pregnancy. These include 17β-estradiol, progesterone, prostaglandins, 
relaxin, oxytocin, vasopressin, inhibin, vascular endothelial growth 
factor, endothelin-1 (ET-1), and prorenin (Ebisch et al., 2008; Kampfer 
et al., 2014). In the absence of pregnancy, the corpus luteum will cease 
synthesis and the structure will regress in size over time (Rowan et al., 
2008). 
Given the suboptimal maternal hemodynamic adaptation in preg-
nancies lacking a corpus luteum, it is likely that this insufficient adap-
tation relies at least also on one or more of the factors released by the 
corpus luteum into the circulation. Prorenin is produced by the mature 
ovarian follicle and the corpus luteum in response to gonadotropin 
stimulation (Derkx et al., 1987). Its levels directly relate to the number 
of ovarian follicles, with a modifying role for the hormones applied in 
the in-vitro fertilization (IVF) protocol (Itskovitz and Sealey, 1987; 
Itskovitz et al., 1987; Wiegel et al., 2020). The former also applies to 
relaxin, which, unlike prorenin, is exclusively produced by the corpus 
luteum (Weiss et al., 1993; Mushayandebvu et al., 1998; Arthur et al., 
1996; Haning et al., 1996; Kristiansson et al., 1996; Conrad et al., 
2019a). In other words, relaxin is entirely absent in pregnancies lacking 
a corpus luteum. Relaxin causes relaxation via NO and prostacyclin, and 
thus potentially contributes to the systemic and renal vasodilation and 
the increase in GFR in early pregnancy. Indeed, the absence of relaxin 
associated with a diminished increase in GFR and higher serum sodium 
and creatinine levels. Moreover, lower relaxin levels ultimately promote 
preeclampsia (Conrad and Davison, 2014; Post Uiterweer et al., 2020). 
Relaxin also stimulates prorenin production (Poisner et al., 1990). 
Finally, estrogens promote vasodilation via NO and prostacyclin, by 
stimulating endothelial NO synthase (eNOS) and cyclooxygenase-1, 
respectively. This increases blood flow, particularly in the uterine 
vascular bed. The latter likely involves 17β-estradiol-induced upregu-
lation of dilator AT2 receptors (Mishra et al., 2019). As discussed, es-
trogen additionally upregulates angiotensinogen, allowing an increase 
in Ang II levels. Simultaneously, estrogens stimulate 11β-hydroxysteroid 
dehydrogenase 2, thereby preventing glucocorticoids from increasing 
blood pressure via binding to mineralocorticoid receptors (Baggia et al., 
1990). Progesterone, like 17β-estradiol, promotes vasodilation via eNOS 
and cyclooxygenase-1 (Simoncini et al., 2007; Hermenegildo et al., 
2005), and is thus able to antagonize Ang II-induced vasoconstriction 
(Nakamura et al., 1988). Summarizing, the corpus luteum secretes 
multiple factors that, through modulation of circulating RAAS activity, 
affect maternal hemodynamic adaptation to pregnancy (Fig. 4). Yet, 
why it secretes prorenin in large amounts cannot be deduced from the 
above findings. A further possibility is that prorenin exerts effects 
locally, in the ovaries, uterus and/or placenta. 
4. Prorenin synthesis in the ovaries, uterus and placenta: does it 
have a local function? 
Extrarenal cells that synthesize prorenin during pregnancy include 
theca cells, chorionic cells, decidual cells and placental cytotropho-
blasts. Prorenin, in contrast to renin, is not stored in vesicles, and thus its 
local synthesis is likely to result in direct release, yielding high prorenin 
levels in the immediate surrounding of prorenin-synthesizing cells, i.e., 
in follicular, chorionic, and amniotic fluid. Indeed, chorionic prorenin 
levels were the highest ever measured in the human body: they 
amounted to 1000 times the normal prorenin levels in the circulation 
(Itskovitz et al., 1992). At such high levels, given that up to 1% of 
prorenin occurs in the open (active) conformation (Schalekamp et al., 
2008), Ang I generation is likely to take place even in the absence of any 
prorenin-renin conversion. In fact, assuming that sufficient angiotensi-
nogen is available, the degree of Ang I generation under such conditions 
might be 100 times above the normal PRA. This implies that this pro-
renin, at least locally, is capable of promoting Ang II-mediated effects. 
4.1. Ovaries 
Prorenin levels in follicular fluid are approximately 10-fold higher 
than those in plasma, both in normal and stimulated menstrual cycles 
(Fernandez et al., 1985; Glorioso et al., 1986). Theca cells of the follicle 
and the luteinized thecal cells of the corpus luteum after ovulation are 
the source of this prorenin. Prorenin synthesis occurs in response to the 
gonadotropic hormones LH and hCG, and involves the adenylyl cycla-
se–cyclic adenosine monophosphate (cAMP) pathway (Sealey et al., 
1985; Itskovitz et al., 1987; Brunswig-Spickenheier and Mukhopadhyay, 
2003; Do et al., 1988). Activation of protein kinase C (PKC), e.g. by 
tumor necrosis factor (TNF)-α, inhibits this process (Brunswig-Spick-
enheier and Mukhopadhyay, 1993). High follicular prorenin levels 
correlate with atresia (characterized by high testosterone levels and a 
low estradiol/progesterone ratio, together resulting in granulosa cell 
degeneration), while low follicular prorenin levels associate with 
immature follicles (Itskovitz et al., 1991). In other words, follicular 
prorenin levels should be in an ideal range, and not be too low or too 
high. Possibly, this is related to the need for ‘optimal’ Ang II levels. 
Multiple effects of Ang II in the ovaries have been described, ranging 
from stimulation of steroidogenesis to oocyte maturation, ovulation and 
atresia (Itskovitz et al., 1991; Cornwallis et al., 1990; Yoshimura et al., 
1992; Peterson et al., 1993; Pellicer et al., 1988; Morris and Paulson, 
1993; Paulson et al., 1989; McNatty et al., 1979; Seibel et al., 1989; 
Lightman et al., 1987). Ang II might also display vascular effects in the 
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follicular microcirculation (affecting blood flow) and facilitate the 
process of neovascularization that is required for appropriate corpus 
luteum formation (Fernandez et al., 1985; Stirling et al., 1990). Many of 
these Ang II effects are controversial (Naftolin et al., 1989; Yoshimura, 
1997). Both AT1 and AT2 receptor stimulation have been implied, with 
the AT2 receptor being the predominant Ang II receptor in the ovaries 
(Yoshimura et al., 1996). Here it is of interest to note that AT2 receptor 
stimulation requires higher Ang II levels than AT1 receptor stimulation 
Fig. 4. The corpus luteum secretes multiple factors that directly or indirectly modulate circulating RAAS activity and affect maternal hemodynamic adaptation 
during early human pregnancy. Progesterone acts as a mineralocorticoid receptor antagonist, thus blocking the effects of aldosterone. Ang, angiotensin; AT1R, 
angiotensin II type 1 receptor and AT2R, angiotensin II type 2 receptor; GFR, glomerular filtration rate; MAP, mean arterial pressure; Na+, sodium; NO, nitric oxide; 
RPF, renal plasma flow. 
Fig. 5. Local prorenin synthesis in the ovaries, uteroplacental unit and fetal membranes, known stimulators and inhibitors of prorenin synthesis, and possible 
functions (local and systemic) of prorenin. ATP, adenosine triphosphate; Ca2+, extracellular calcium; cAMP, cyclic adenosine monophosphate; hCG, human chorionic 
gonadotropin; PDE, phosphodiesterase; PDEi, phosphodiesterase inhibitor; PKC, protein kinase C; TNF, tumor necrosis factor; VEGF, vascular endothelial 
growth factor. 
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(Schalekamp and Danser, 2013). Thus, high prorenin levels might 
indeed lead to Ang II levels that are high enough to stimulate atresia via 
AT2 receptor stimulation (Kotani et al., 1999). Prostaglandins often act 
as intermediates, and since both AT receptors upregulate different 
prostaglandins this may explain part of the controversy (Jaiswal et al., 
1991; Glance et al., 1985). After decades of work, the only unifying 
concept is that the ovarian Ang II effects occur in a model- and 
species-dependent manner. 
4.2. Uteroplacental unit 
The decidua, the maternal bed of the placenta, originates from 
differentiating endometrial stroma cells. This ‘decidualization’ process 
(involving cell growth, proliferation and angiogenesis) is primarily co-
ordinated by ovarian steroids (Shah et al., 1991). It occurs during the 
secretory phase of the endometrial cycle, to prepare the receptive 
endometrium for implantation, and is maintained during pregnancy. 
Both the endometrium and decidua release prorenin, although quanti-
tatively the decidual contribution is most important (Shaw et al., 1989). 
Most groups investigating prorenin release from decidual cells addi-
tionally find ‘renin’ activity, i.e., Ang I-generating activity even without 
converting prorenin to renin. Yet, in reality this represents the fact that, 
as discussed, a small fraction of prorenin occurs in the open conforma-
tion (Fig. 5) (Martini et al., 2017). Martini et al. investigated whether 
decidual cells possibly release prorenin in the ‘open’ conformation, 
based on the concept that the low pH conditions under which its syn-
thesis and release occur favor the open conformation (Schalekamp et al., 
2008). If so, prorenin would display local activity, in the immediate 
surrounding of its release, before returning to its closed, inactive 
conformation at greater distance from its release site. Unfortunately, no 
evidence for this concept could be obtained. Among the stimulators of 
decidual prorenin synthesis are progesterone (Shah et al., 1991) and 
relaxin (Poisner et al., 1990). Remarkably, ET-1, known to suppress 
renin synthesis in the kidney (Verdonk et al., 2015), actually stimulated 
decidual prorenin production (Poisner et al., 1990; Chao et al., 1993), 
while TNF-α, interleukin-1β and interferon-γ inhibited it (Poisner et al., 
1991; Jikihara et al., 1995, 1996). Like in theca cells, the adenylyl 
cyclase–cAMP pathway is the intracellular mediator of this process, with 
modulatory roles for PKC and calcium (Poisner et al., 1991; Chao et al., 
1994). Decidual prorenin production has been linked to vascular 
endothelial growth factor expression through local RAAS activation 
(Lumbers et al., 2015). Since vascular endothelial growth factor is a 
well-known contributor to de novo vessel formation, prorenin may thus 
facilitate decidualization. Interestingly, altered endometrial AT1 and 
AT2 receptor expression has been suggested to underlie recurrent 
miscarriage (Qi et al., 2020). 
The placental cells that synthesize prorenin are the cytotrophoblasts 
(Poisner et al., 1994). Cytotrophoblasts decrease in number during 
gestation, when they fuse to syncytiotrophoblasts. As a consequence, 
placental prorenin levels are low at term, and hence prorenin release 
into the maternal circulation at the end of pregnancy will be similarly 
low. Stimulators of placental prorenin production are hCG and β-adre-
noceptor agonists (Downing et al., 1994). This involves the adenylyl 
cyclase–cAMP pathway (Poisner et al., 1994; Downing et al., 1994). 
Phosphodiesterase inhibitors (blocking cAMP degradation) further 
upregulate prorenin release (Poisner et al., 1994; Downing et al., 1996), 
while Ang II and TNF-α block it (Poisner, 1995). 
The fetal membranes, chorion and the amnion, originate from the 
outer trophoblast layer of the implanting blastocysts. Only chorionic 
cells (cytotrophoblasts) synthesize and release prorenin (Pinet et al., 
1988; Duncan et al., 1990). Prorenin is capable of passing through the 
amnion, thus explaining why amniotic fluid contains high prorenin 
levels, despite the fact that amniotic cells do not synthesize prorenin 
(Acker et al., 1982; Itskovitz et al., 1992). A potential candidate facili-
tating prorenin passage is megalin (Sun et al., 2020). Megalin is a 600 
kDa endocytic receptor, highly expressed in placental 
syncytiotrophoblasts, which is thought to contribute to transport func-
tions (Akour et al., 2013). Decidual cells are an unlikely source of pro-
renin in the gestational sac, given the fact that the gestational prorenin 
levels were normal in tubal pregnancy, when decidualization is absent 
(Itskovitz et al., 1992). Chorionic prorenin synthesis depends on cAMP, 
PKC and extracellular calcium (Duncan et al., 1990). To what degree the 
high prorenin levels in chorionic and amniotic fluid play a role beyond 
Ang II formation remains a matter of debate. Possible roles of Ang II 
concern its effects on angiogenesis, growth and vascular con-
striction/dilation (the latter mediated via vasodilator prostanoids) 
(Fernandez et al., 1985; Glance et al., 1985; Magness et al., 1992; Anton 
et al., 2008; Pringle et al., 2011; Franklin et al., 1974). 
5. Prorenin and preeclampsia: lessons from animal models 
The hemodynamic adaptation process in pregnancy, i.e. the expan-
sion of plasma volume and the decrease in vascular resistance, is less 
pronounced in preeclampsia (Spaanderman et al., 2001). Pregnancies 
complicated by preeclampsia are characterized by diminished utero-
placental flow (Schuchter et al., 2001), suggesting that the normally 
occurring expansion of plasma volume and increase in cardiac output 
are essential for the maintenance of a sufficient uteroplacental flow. 
Remarkably, despite this reduction in circulating volume, renin and 
angiotensinogen are downregulated in preeclampsia compared with 
normal pregnancy (Verdonk et al., 2015). Whether this is a physiological 
response to the increased blood pressure or an active contributor to the 
pathophysiology of preeclampsia is unknown. Circulating prorenin 
levels in preeclampsia are in the normal range (Nicholson et al., 1987; 
Verdonk et al., 2015; Brar et al., 1987), although data during early 
pregnancy in this condition are lacking. Thus, we do not know whether 
the follicular/corpus luteum release of prorenin in early pregnancy is 
altered in women who develop preeclampsia. Data on prorenin levels in 
the uteroplacental unit (chorion, amnion, placenta) of preeclamptic 
women are conflicting, with evidence for decreases, increases and no 
alteration (Brar et al., 1987; Singh et al., 2004; Kalenga et al., 1996; 
Poranen et al., 2009; Herse et al., 2007). The rise in ET-1 in preeclampsia 
(Verdonk et al., 2015), given its stimulatory effect on prorenin release in 
decidual cells (Chao et al., 1993), might support local prorenin upre-
gulation. Nevertheless, in view of the normal circulating prorenin levels 
in preeclamptic women, prorenin upregulation, if occurring at all in 
either ovaries or the uteroplacental unit, is most likely modest. Herse 
observed decidual AT1 receptor upregulation in preeclamptic women, 
and no change in decidual and placental renin, angiotensinogen or ACE, 
nor AT1 receptor upregulation in the placenta (Herse et al., 2007). From 
these gene expression studies, it is difficult to conclusively state that 
there is selective RAAS upregulation at one or more sites in the utero-
placental unit. 
In 1996, a mouse model was described with severe maternal hy-
pertension during pregnancy, when mating transgenic females 
expressing human angiotensinogen with males expressing human renin 
(Takimoto et al., 1996). Here it is important to note that human renin 
does not react with mouse angiotensinogen (and vice versa), so that the 
single transgenic mice did not have a hypertensive phenotype. Inter-
estingly, pregnancy-associated hypertension did not occur when 
crossing females expressing human renin with males expressing human 
angiotensinogen. The authors concluded that the placenta releases renin 
but not angiotensinogen into the circulation. Indeed, human renin could 
be demonstrated in maternal plasma at levels of 2.7 ng/mL, i.e., around 
1000 times the normal renin level in humans (Campbell et al., 2009). 
Importantly, human prorenin levels in these mice were 57 ng/mL, which 
is also around 3 orders of magnitude above its normal levels in humans 
(and 100 times above the prorenin levels in pregnant women). Thus, in 
full agreement with the observations in humans, the placental release 
largely concerned prorenin. Furthermore, given that the human renin 
levels represented only a small fraction of the total human renin levels, it 
is likely that this in reality was prorenin in the open, active 
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conformation. The fact that there was no placental angiotensinogen 
release suggests that either angiotensinogen, unlike (pro)renin, cannot 
be released from its placental generation sites, or that there simply is no 
placental angiotensinogen production. The latter explanation is the most 
likely, since the placental angiotensinogen levels, unlike those of pro-
renin, are identical at different placental tissue sites (chorion leave, 
amnion, chorion plate and chorion fondrosum) (Lenz et al., 1989). This 
argues against a specific production site. Moreover, placental angio-
tensinogen is washed away during perfusion with buffer (Lenz et al., 
1991). The fact that the follicular/amniotic fluid levels resemble those in 
plasma suggests that also in the ovaries, angiotensinogen is derived from 
maternal blood (Glorioso et al., 1986; Paulson et al., 1989). 
The double transgenic approach (human angiotensinogen females x 
human renin males) also yielded hypertension, proteinuria and growth 
restriction in pregnant rats, and this model is therefore suggested to be 
representative for preeclampsia. These rats displayed a PRA that was 
roughly 100 times the normal PRA in pregnant women (Verdonk et al., 
2015; Bohlender et al., 2000), while their angiotensinogen levels were in 
the normal pregnancy range. Human prorenin levels were not deter-
mined in this model. But given that normally the placental contribution 
to plasma prorenin in pregnancy is <5% (Lenz et al., 1991), and 
assuming that the rise in PRA largely reflects the activity of open pro-
renin, it can be estimated that the placental release of human prorenin in 
these transgenic rodents must have been phenomenally high, possibly 
>10.000 times normal. When combined with human angiotensinogen, it 
is not surprising that this results in severe hypertension. Haase recently 
reported that human angiotensinogen siRNA targeted to the maternal 
liver suppressed the phenotype (Haase et al., 2020), raising the possi-
bility that targeting the maternal RAAS may be beneficial in pre-
eclampsia. However, whether this model truly mimics preeclampsia 
remains doubtful, since in reality preeclamptic women display signifi-
cantly suppressed PRA levels. If the proteinuria and growth restriction in 
this animal model are due to the elevated PRA, this model may turn out 
to be less representative for the human situation. Nevertheless, these 
transgenic studies elegantly support the release of prorenin from the 
uteroplacental unit into blood, and prove that such release, if excessive, 
disturbs the normal maternal hemodynamic adaptation to pregnancy. 
6. Prorenin and (patho)physiology of pregnancy course and 
outcomes 
Most of the adverse pregnancy outcomes are likely to originate in the 
first trimester of pregnancy (Steegers-Theunissen et al., 2013). Insuffi-
cient hemodynamic adaptation preconception and during early preg-
nancy may also underlie fetal growth restriction (FGR) (Duvekot et al., 
1995; Vasapollo et al., 2004; Salas et al., 2006; De Paco et al., 2008). To 
what degree this concerns suppressed circulating RAAS activation (like 
in preeclampsia) is unknown, although an impaired plasma volume 
expansion in the third trimester and low birthweight have been linked to 
low PRA and circulating aldosterone levels in late pregnancy (Salas and 
Rosso, 1998; Salas et al., 2006). Moreover, first trimester plasma 
angiotensinogen levels correlated positively with birth weight (Al Kadi 
et al., 2005). Since low birth weight is a substantial determinant of a 
child’s health and a major risk factor for several noncommunicable 
diseases (Barker, 2007), these data indicate that dysregulated circu-
lating RAAS activation in early pregnancy may also affect health later in 
life. 
Low follicular/amniotic fluid prorenin levels might reduce local 
RAAS activity, thus diminishing the growth-stimulating and angiogenic 
effects of Ang II. A downregulation of placental AT1 receptors, as 
observed in FGR pregnancies (Knock et al., 1994; Li et al., 1998), would 
have a similar effect. 
Pregnancies achieved through IVF treatment are characterized by 
more frequent early and late vascular-related pregnancy complications. 
The risk factors for these complications are identical to those for women 
who conceive naturally and develop pregnancy complications, and 
include high maternal age, a high body mass index, chronic hyperten-
sion and diabetes mellitus (Bartsch et al., 2016). These risk factors are 
characterized by RAAS alterations and oxidative stress. For instance, 
diabetes mellitus, like pregnancy, associates with high prorenin levels 
(Bryer-Ash et al., 1983; Franken et al., 1990). Interestingly, pregnant 
women with diabetes mellitus who additionally develop preeclampsia 
displayed the highest prorenin levels (Ringholm et al., 2011). Oxidative 
stress impacts placental health during the critical hypoxic state (Jau-
niaux et al., 2006; Burton et al., 2003) This may affect local renin 
regulation via epigenetic pathways (Wang et al., 2013). 
7. Conclusions and future directions 
Prorenin is among the factors released by the corpus luteum that 
determine maternal hemodynamic adaptation in early gestation. Animal 
data suggest that prorenin release by the placenta, if excessive, leads to 
hypertension, proteinuria and growth restriction. There is no evidence 
for conversion of this ovarian/placental prorenin to renin, and normally, 
at most a very small fraction of prorenin displays Ang I-generating ac-
tivity without prosegment removal. This implies that only under con-
ditions where prorenin release is far beyond normal (like in transgenic 
animals) such prorenin rises would substantially upregulate Ang II 
generation in the circulation. In humans this might also be the case in 
chorionic fluid, with its prorenin levels that are >1000-fold those in 
blood, and possibly in the immediate surrounding of cells that synthe-
size prorenin in the decidua and placenta. The angiotensinogen that is 
needed to allow local prorenin activity is of maternal origin, implying 
that it must be capable of passing the placental barrier. Angiotensinogen 
siRNA targeted to the maternal liver may thus help to prevent excessive 
RAAS activation, both in the mother and fetus. However, the pregnancy 
complication preeclampsia is characterized by low RAAS activity, and 
this may also be true for FGR. A wide range of local effects of Ang II in 
the ovary and uteroplacental unit has been described, ranging from 
oocyte maturation and decidualization to angiogenesis and regional 
blood flow modification. A remaining question is whether prorenin ex-
erts effects beyond Ang II. Here its interaction with the (pro)renin re-
ceptor is of interest, although even the prorenin rises in pregnancy 
appear to be too limited to match the nanomolar affinity of this receptor. 
It has been argued that prorenin is a direct vasodilator, but the under-
lying mechanism remains unknown. A novel prorenin receptor is meg-
alin, a transporter protein which is also abundantly present in the 
placenta. Its relationship with prorenin in the placenta remains to be 
determined. Future studies correlating prorenin levels with utero 
(placental) outcome and oxidative stress parameters could help to 
further determine the function of this prohormone. Careful linking of 
prorenin to other corpus luteum factors, corpus luteum number and IVF 
protocol will yield insight into its regulation and release. Here both 
relaxin and ET-1 are of great interest as prorenin modifiers. Low or 
absent relaxin levels (as occurring in women without a corpus luteum) 
promote preeclampsia, while ET-1 is upregulated in this condition. Since 
both relaxin and ET-1 upregulate prorenin, a unifying hypothesis might 
be that prorenin levels need to be in a specific range to allow optimal 
Ang II formation, with for instance too low levels resulting in insufficient 
AT1 receptor stimulation (required for corpus luteum formation and 
decidualization), and too high levels leading to deleterious AT2 receptor 
stimulation (inducing atresia). 
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Nguyen, G., Delarue, F., Burcklé, C., et al., 2002. Pivotal role of the renin/prorenin 
receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 
109, 1417–1427. 
Nice, M., 1935. Kidney Function during Normal Pregnancy I. The increased urea 
clearance of normal pregnancy. J. Clin. Invest. 14, 575–578. 
Nicholson, E.C., Gallery, E.D.M., Brown, M.A., et al., 1987. Renin activation in normal 
and hypertensive human pregnancy. Pregnancy Hypertens. 6, 453–464. 
Paulson, R.J., Do, Y.S., Hsueh, W.A., et al., 1989. Ovarian renin production in vitro and 
in vivo: characterization and clinical correlation. Fertil. Steril. 51, 634–638. 
Pellicer, A., Palumbo, A., DeCherney, A.H., et al., 1988. Blockage of ovulation by an 
angiotensin antagonist. Science 240, 1660–1661. 
Peterson, C.M., Zhu, C., Mukaida, T., et al., 1993. The angiotensin II antagonist saralasin 
inhibits ovulation in the perfused rat ovary. Am. J. Obstet. Gynecol. 168, 242–245. 
Pinet, F., Corvol, M.-T., Bourguignon, J., et al., 1988. Isolation and characterization of 
renin-producing human chorionic cells in culture. J. Clin. Endocrinol. Metab. 67, 
1211–1220. 
Poisner, A.M., 1995. Regulation of utero-placental prorenin. Adv. Exp. Med. Biol. 377, 
411–426. 
Poisner, A.M., Downing, G.J., Poisner, R., 1994. Prorenin secretion from villous placenta: 
regulation by cyclic AMP and angiotensin. Placenta 15, 487–499. 
Poisner, A.M., Thrailkill, K., Poisner, R., et al., 1990. Relaxin stimulates the synthesis and 
release of prorenin from human decidual cells: evidence for autocrine/paracrine 
regulation. J. Clin. Endocrinol. Metab. 70, 1765–1767. 
Poisner, A.M., Thrailkill, K., Poisner, R., et al., 1991. Cyclic AMP as a second messenger 
for prorenin release from human decidual cells. Placenta 12, 263–267. 
Poranen, A.-K., Aalto, M., Matinlauri, I., et al., 2009. Total renin in preeclamptic 
placenta. Hypertens. Pregnancy 15, 347–352. 
Post Uiterweer, E.D., Koster, M.P.H., Jeyabalan, A., et al., 2020. Circulating pregnancy 
hormone relaxin as a first trimester biomarker for preeclampsia. Pregnancy 
Hypertens. 22, 47–53. 
Pringle, K.G., Conquest, A., Mitchell, C., et al., 2015. Effects of fetal sex on expression of 
the (pro)renin receptor and genes influenced by its interaction with prorenin in 
human amnion. Reprod. Sci. 22, 750–757. 
Pringle, K.G., Tadros, M.A., Callister, R.J., et al., 2011. The expression and localization of 
the human placental prorenin/renin- angiotensin system throughout pregnancy: 
roles in trophoblast invasion and angiogenesis? Placenta 32, 956–962. 
Qi, R., Li, T.C., Chen, X., 2020. The role of the renin–angiotensin system in regulating 
endometrial neovascularization during the peri-implantation period: literature 
review and preliminary data. Ther. Adv. Endocrinol. Metabol. 11, 
2042018820920560.  
Ren, L., Sun, Y., Lu, H., et al., 2018. (Pro)renin receptor inhibition reprograms hepatic 
lipid metabolism and protects mice from diet-induced obesity and hepatosteatosis. 
Circ. Res. 122, 730–741. 
Ringholm, L., Pedersen-Bjergaard, U., Thorsteinsson, B., et al., 2011. A high 
concentration of prorenin in early pregnancy is associated with development of pre- 
eclampsia in women with type 1 diabetes. Diabetologia 54, 1615–1619. 
Robb, A.O., Mills, N.L., Din, J.N., et al., 2009. Influence of the menstrual cycle, 
pregnancy, and preeclampsia on arterial stiffness. Hypertension 53, 952–958. 
Roberts, M., Lindheimer, M.D., Davison, J.M., 1996. Altered glomerular permselectivity 
to neutral dextrans and heteroporous membrane modeling in human pregnancy. Am. 
J. Physiol. 270, F338–F343. 
Robson, S.C., Hunter, S., Boys, R.J., et al., 1989. Serial study of factors influencing 
changes in cardiac output during human pregnancy. Am. J. Physiol. 256, 
H1060–H1065. 
Rowan, K., Meagher, S., Teoh, M., et al., 2008. Corpus luteum across the first trimester: 
size and laterality as observed by ultrasound. Fertil. Steril. 90, 1844–1847. 
Salas, S.P., Marshall, G., Gutierrez, B.L., et al., 2006. Time course of maternal plasma 
volume and hormonal changes in women with preeclampsia or fetal growth 
restriction. Hypertension 47, 203–208. 
R.E. Wiegel et al.                                                                                                                                                                                                                                
Molecular and Cellular Endocrinology 522 (2021) 111118
10
Salas, S.P., Rosso, P., 1998. Plasma volume, renal function, and hormonal levels in 
pregnant women with idiopathic fetal growth restriction or preeclampsia. 
Hypertens. Pregnancy 17, 69–79. 
Schalekamp, M.A., Derkx, F.H., Deinum, J., et al., 2008. Newly developed renin and 
prorenin assays and the clinical evaluation of renin inhibitors. J. Hypertens. 26, 
928–937. 
Schalekamp, M.A.D.H., Danser, A.H.J., 2013. How does the angiotensin II type 1 receptor 
’trump’ the type 2 receptor in blood pressure control? J. Hypertens. 31, 705–712. 
Schuchter, K., Metzenbauer, M., Hafner, E., et al., 2001. Uterine artery Doppler and 
placental volume in the first trimester in the prediction of pregnancy complications. 
Ultrasound Obstet. Gynecol. 18, 590–592. 
Sealey, J.E., Catanzaro, D.F., Lavin, T.N., et al., 1996. Specific prorenin/renin binding 
(ProBP) identification and characterization of a novel membrane site. Am. J. 
Hypertens. 9, 491–502. 
Sealey, J.E., McCord, D., Taufield, P.A., et al., 1985. Plasma prorenin in first-trimester 
pregnancy: relationship to changes in human chorionic gonadotropin. Am. J. Obstet. 
Gynecol. 153, 514–519. 
Sealey, J.E., von Lutterotti, N., Rubattu, S., et al., 1991. The greater renin system. Its 
prorenin-directed vasodilator limb. Relevance to diabetes mellitus, pregnancy, and 
hypertension. Am. J. Hypertens. 4, 972–977. 
Seibel, M.M., Smith, D., Dlugi, A.M., et al., 1989. Periovulatory follicular fluid hormone 
levels in spontaneous human cycles. J. Clin. Endocrinol. Metab. 68, 1073–1077. 
Shah, D.M., Higuchi, K., Inagami, T., et al., 1991. Effect of progesterone on renin 
secretion in endometrial stromal, chorionic trophoblast, and mesenchymal 
monolayer cultures. Am. J. Obstet. Gynecol. 164, 1145–1150. 
Shaw, K.J., Do, Y.S., Kjos, S., et al., 1989. Human decidua is a major source of renin. 
J. Clin. Invest. 83, 2085–2092. 
Simoncini, T., Fu, X.D., Caruso, A., et al., 2007. Drospirenone increases endothelial nitric 
oxide synthesis via a combined action on progesterone and mineralocorticoid 
receptors. Hum. Reprod. 22, 2325–2334. 
Sims, E.A., Krantz, K.E., 1958. Serial studies of renal function during pregnancy and the 
puerperium in normal women. J. Clin. Invest. 37, 1764–1774. 
Singh, H.J., Rahman, A., Larmie, E.T., et al., 2004. Raised prorenin and renin 
concentrations in pre-eclamptic placentae when measured after acid activation. 
Placenta 25, 631–636. 
South, A.M., Shaltout, H.A., Washburn, L.K., et al., 2019. Fetal programming and the 
angiotensin-(1-7) axis: a review of the experimental and clinical data. Clin. Sci. 
(Lond.) 133, 55–74. 
Spaanderman, M., Ekhart, T., Van Eyck, J., et al., 2001. Preeclampsia and maladaptation 
to pregnancy: a role for atrial natriuretic peptide? Kidney Int. 60, 1397–1406. 
Steegers-Theunissen, R.P., Twigt, J., Pestinger, V., et al., 2013. The periconceptional 
period, reproduction and long-term health of offspring: the importance of one- 
carbon metabolism. Hum. Reprod. Update 19, 640–655. 
Stirling, D., Magness, R.R., Stone, R., et al., 1990. Angiotensin II inhibits luteinizing 
hormone-stimulated cholesterol side chain cleavage expression and stimulates basic 
fibroblast growth factor expression in bovine luteal cells in primary culture. J. Biol. 
Chem. 265, 5–8. 
Sun, Y., Goes Martini, A., Janssen, M.J., et al., 2020. Megalin: a novel endocytic receptor 
for prorenin and renin. Hypertension 75, 1242–1250. 
Takimoto, E., Ishida, J., Sugiyama, F., et al., 1996. Hypertension induced in pregnant 
mice by placental renin and maternal angiotensinogen. Science 274, 995–998. 
Uijl, E., Mirabito Colafella, K.M., Sun, Y., et al., 2019. Strong and sustained 
antihypertensive effect of small interfering RNA targeting liver angiotensinogen. 
Hypertension 73, 1249–1257. 
Vasapollo, B., Valensise, H., Novelli, G.P., et al., 2004. Abnormal maternal cardiac 
function precedes the clinical manifestation of fetal growth restriction. Ultrasound 
Obstet. Gynecol. 24, 23–29. 
Verdonk, K., Saleh, L., Lankhorst, S., et al., 2015. Association studies suggest a key role 
for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin- 
angiotensin-aldosterone system suppression. Hypertension 65, 1316–1323. 
Verdonk, K., Visser, W., Van Den Meiracker, A.H., et al., 2014. The renin-angiotensin- 
aldosterone system in pre-eclampsia: the delicate balance between good and bad. 
Clin. Sci. (Lond.) 126, 537–544. 
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